Literature DB >> 31595083

CGRP-targeted antibodies in difficult-to-treat migraine.

Tessa de Vries1, Antoinette MaassenVanDenBrink2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31595083     DOI: 10.1038/s41582-019-0275-0

Source DB:  PubMed          Journal:  Nat Rev Neurol        ISSN: 1759-4758            Impact factor:   42.937


× No keyword cloud information.
  4 in total

1.  Cytokine activin C ameliorates chronic neuropathic pain in peripheral nerve injury rodents by modulating the TRPV1 channel.

Authors:  Ya-Kun Huang; Yu-Gang Lu; Xin Zhao; Jing-Bing Zhang; Feng-Ming Zhang; Yong Chen; Ling-Bo Bi; Jia-Hui Gu; Zuo-Jie Jiang; Xiao-Man Wu; Qing-Yi Li; Yanli Liu; Jian-Xin Shen; Xing-Jun Liu
Journal:  Br J Pharmacol       Date:  2020-11-16       Impact factor: 8.739

2.  Amylin Analog Pramlintide Induces Migraine-like Attacks in Patients.

Authors:  Hashmat Ghanizada; Mohammad Al-Mahdi Al-Karagholi; Christopher S Walker; Nanna Arngrim; Tayla Rees; Jakeb Petersen; Andrew Siow; Mette Mørch-Rasmussen; Sheryl Tan; Simon J O'Carroll; Paul Harris; Lene Theil Skovgaard; Niklas Rye Jørgensen; Margaret Brimble; Jayme S Waite; Brandon J Rea; Levi P Sowers; Andrew F Russo; Debbie L Hay; Messoud Ashina
Journal:  Ann Neurol       Date:  2021-04-08       Impact factor: 11.274

3.  Role of CGRP pathway polymorphisms in migraine: a systematic review and impact on CGRP mAbs migraine therapy.

Authors:  Damiana Scuteri; Maria Tiziana Corasaniti; Paolo Tonin; Pierluigi Nicotera; Giacinto Bagetta
Journal:  J Headache Pain       Date:  2021-07-30       Impact factor: 7.277

Review 4.  Migraine Prevention with Erenumab: Focus on Patient Selection, Perspectives and Outcomes.

Authors:  Eleonora De Matteis; Simona Sacco; Raffaele Ornello
Journal:  Ther Clin Risk Manag       Date:  2022-04-05       Impact factor: 2.423

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.